You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

425 Results
Document
New
Apr 2025
Document
New
Apr 2025
Document
New
Apr 2025
Document
New
Apr 2025
Guidelines and Advice
Status: Current
ID: GL 1-14
Version: 3
Oct 2019
Guidelines and Advice
Status: In-Review
ID: 19-4
May 2015
Guidelines and Advice
Status: Archived
ID: 15-15
Sep 2017
Guidelines and Advice
Status: In-Review
ID: 15-12
Version: 2
Jan 2015
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - In Combination with Pomalidomide and Dexamethasone for Previously Treated Multiple Myeloma
ODB - General Benefit
    dexamethasone
Exceptional Access Program
    pomalidomide - In combination with bortezomib and dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma, based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
bortezomib,
dexamethasone,
pomalidomide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2025
Document
New
May 2025
Document
New
May 2025
Document
New
May 2025

Pages